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Treatment
Abstract In this chapter the treatment of drug sensitive and drug resistant TB and
timing of antiretroviral treatment for HIV infected patients will be reviewed.
Emphasis is placed on results of recent trials of fluoroquinolones for treatment
shortening of drug sensitive TB. The use of two relatively novel agents in MDR-TB
treatment, bedaquiline and delamanid, will be discussed.
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5.1 First-Line Antituberculous Treatment
The introduction of rifampicin to the ﬁrst-line combination regimen in the late
1970s allowed the shortening of treatment for TB from 18–24 months to 6 months.
This “short-course” regimen, consists of an ‘intensive phase’ of 4 ﬁrst line drugs;
ethambutol (EMB) [or streptomycin (SM)], isoniazid (INH), pyrazinamide (PZA)
and rifampicin (RIF) for 2 months followed by a ‘continuation phase’ of 2 months
of RIF and INH (Table 5.1). The continuation phase may be extended in more
complex cases and some countries still use an 8-month standard regimen which is
no longer recommended by WHO. Ethambutol should be used in place of the
injectable streptomycin where possible for HIV-infected individuals. Since the
development of the short-course regimen, standard TB-treatment has remained
largely unchanged for the past 40 years. Daily, directly observed therapy (DOT) is
preferable to intermittent regimens and ﬁxed dose combination (FDC) drugs may be
used to ensure multi-drug therapy (Nunn et al. 2014). Pyridoxine should be
administered with isoniazid to prevent peripheral neuropathy. The historic events
that have led to the current treatment schedule are comprehensively reviewed by
Diacon and colleagues (Diacon et al. 2012).
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Group 1: ﬁrst-line oral drugs


























Second-line drugs (group 2, injectables)









Kanamycin (Km) 15–20 mg/kg
[1000 mg]
15–30 [1000] Renal failure
(usually reversible)
























Moxifloxacin (Mfx) 400 mg daily
dose
7.5–10















Group 4: oral bacteriostatic second-line













Unable to tolerate 1
g as a single dose




Terizidone (Trd) 15–20 mg/kg
[900 mg]






Cycloserine (Cs) 15–20 mg/kg
[1000 mg]
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WHO treatment guidelines can be found at http://www.who.int/tb/publications/
tb_treatmentguidelines/en/index.html. Treatment recommendations for pediatric TB
were revised in 2010, with an increased dose of all ﬁrst-line drugs (http://
whqlibdoc.who.int/publications/2010/9789241500449_eng.pdf) and a request not











Group 5: Agents with unclear role in treatment of drug resistant-TBc
























16–20 mg/kg/day Hepatitis; peripheral
neuropathy











Delaminid 200 mg twice
daily
QT prolongation
aHypersensitivity reactions and drug rashes may occur with any anti-tuberculous drug
bPyridoxine should be given with isoniazid to prevent peripheral neuropathy. Guidelines variously
recommend 10 or 25 mg/kg daily
cOptimal dose and long-term safety not well established for group 5 drugs
dDo not use thioazetone for HIV-infected individuals (signiﬁcant risk of Stevens-Johnson
syndrome)
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2014). This followed systematic review of evidence showing that children achieve
inadequate serum exposure when receiving the same dose/kg as adults and there
was no evidence of adverse toxicity from the higher doses. Pharmacokinetic data
from South Africa showed substantially improved serum levels with the novel
regimen but it remains to be demonstrated if these doses are sufﬁcient to achieve
improved outcomes (Thee et al. 2011).
5.2 HIV Associated Tuberculosis
The advent of HIV has severely impacted the burden of TB. All HIV patients
should be screened for TB and all TB patients should be offered HIV testing. Dual
treatment of HIV and TB is complex, as patients are faced with a higher pill-burden,
increased risk of toxicity, drug-interactions and IRIS (Lawn et al. 2013; Lai et al.
2013). Routine administration of co-trimoxazole (960 mg/day) is recommended in
all patients with HIV-associated TB, since it has been shown to substantially reduce
mortality in patients in Sub Saharan Africa. Rifampicin is an inducer of the cyto-
chrome P450 2B6 enzyme, which is the main pathway for the non-nucleaside
reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) either of
which are the basis of ARV treatment (Bonnet et al. 2013). The most commonly
used NNRTI is efavirenz. Although the US FDA recommends that the dose of
efavirenz should be increased when co-administered with rifampicin, this is not
substantiated in the most recent clinical trials, which show excellent virological
response in those patients receiving standard dose (600 mg) of efavirenz (Kwara
et al. 2010). Nevarapine is an alternative NNRTI used for those patients who cannot
tolerate efavirenz, but plasma levels are very low in patients receiving rifampicin
during the lead-in phase of nevarapine. This may predispose to resistance formation
and virological failure. Dose increase is not recommended because concerns of
toxicity, however it is plausible to omit the 14 day lead-in phase of nevirapine
dosing after the CARENIMO trial showed that nevirapine was well tolerated at full
dose when introduced in patients with CD4 cell counts <250/mm3 while receiving
rifampicin (Bonnet et al. 2013). The co-administration of second-line ARV regi-
mens containing PIs remains a challenge and there is an urgent need for clinical
trials evaluating safety and efﬁcacy. ‘Superboosting’ of ritonavir or doubling dose
of lopinavir/ritanovir combination formulation are suggested, as is substituting ri-
fabutin for rifampicin (Lawn et al. 2013).
Timing of initiation of ARV treatment in ARV-naïve TB/HIV patients has been
evaluated in a recent series of clinical trials published in 2011 (SAPIT
[NCT00398996], CAMELIA[NCT01300481] and the AIDS clinical trial group
study A5221). Results showed that there is a reduction in mortality in patients with
CD4 cell counts lower that 200/mm3 (CAMELIA trial) or 50/mm3 (other two trials)
when ARV treatment was initiated within 2 weeks of TB treatment (GRADE A3),
(Abdool Karim et al. 2010, 2013; Blanc et al. 2011). However this carries an
increased risk of IRIS and treatment toxicity. The management in patients with
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higher CD4 cell counts is less clear and it may be acceptable to defer ARV treat-
ment until the continuation phase of TB treatment. The majority of patients in these
trials had pulmonary TB. For patients with TB meningitis, a recent large
Vietnamese randomised controlled trial showed no beneﬁt of early initiation of
ARVs and deferred treatment at 2 months was associated with less toxicity and less
occurrence of IRIS (Torok et al. 2011). Patients in this cohort had extremely low
median CD4 count and the results may not be generalizable to other populations.
5.3 Treatment of Drug-Resistant Tuberculosis
The use of multi-drug therapy for TB treatment from the early days of discovery of
antituberculous drugs has actually preserved the efﬁcacy of the ﬁve ﬁrst line agents for
TB remarkably well for over 50 years. However, drug resistance inM. tuberculosis is
increasing and has now reached alarming levels, particularly in the former Soviet
states, India, South Africa and part of Asia. Approximately 8 % of M. tuberculosis
cases globally are now resistant to isoniazid. Multi-drug resistant TB (MDR TB) is
deﬁned as TB resistant to at least isoniazid and rifampicin, the two key ﬁrst line drugs
in the treatment regimen. MDR TB is much harder to treat, requiring a minimum of
18 months treatment with expensive, toxic and weak second line drugs. Worldwide,
3.6 % of newly diagnosed and 20 % of patients previously treated for TB have
MDR TB but there are dramatic regional variations with the highest proportion in
Eastern Europe and Central Asia (WHO 2014).
In 2012 there were an estimated 450,000 new cases of MDR TB worldwide and
170,000 deaths but only 17 % were diagnosed and enrolled into high quality
treatment programmes. This ﬁgure does however represent a 42 % increase on
2011, reflecting scale-up efforts for MDR detection and treatment. In 2006 WHO
deﬁned a new category of drug resistant TB as extensively drug resistant TB (XDR
TB). XDR TB is MDR TB additionally resistant to a fluoroquinolone and a second
line injectable drug (amikacin, capreomycin or kanmycin). This followed a docu-
mented outbreak in Kwa-Zulu Natal province of South Africa in which 53 cases of
XDR TB were identiﬁed among HIV patients, all but one of whom died with a
median survival time of 16 days from diagnosis. Following acceptance of the
deﬁnition of XDR TB, 92 countries have reported cases by 2013 (Fig. 5.1). It is
estimated 10 % of MDR cases are in fact XDR and it is now clear that XDR TB is
present in almost every country although the extent of transmission within com-
munities is not established due to the limited availability of second-line drug sus-
ceptibility testing for M. tuberculosis. The term totally drug resistant TB has been
used in the literature to describe M. tuberculosis strains resistant to all ﬁrst and
second line drugs but the use of this term is not recognised by WHO due to the
difﬁculty of standardising drug susceptibility testing for second line drugs and the
introduction of treatment options (Cegielski et al. 2012).
Drug resistant TB should be treated with at least four drugs to which the
organism is susceptible, prioritising any ﬁrst-line agents and then including a
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fluoroquinolone and an injectable agent. In order to protect against drug resistance
ampliﬁcation, a single drug should never be added to a failing regimen (Daley and
Caminero 2013). Key principles of MDR treatment are summarised in Table 5.2
(Kaufmann et al. 2014; Ulrich et al. 2006).
Comprehensive CDC guidelines on both susceptible and drug resistant TB can
be found on http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm.
The painstakingly sluggish decline in incidence of TB and the rise of MDR- and
XDR-TB underlines the inadequacies of current treatment and prevention measures.
Priority questions for research, in addition to the search for novel agents include
shortened regimens, optimal regimens for all forms of drug resistant TB, optimal
dose of drugs (especially rifampicin), and treatment of HIV-associated TB.
Several existing and newly developed compounds are under evaluation for drug-
sensitive and drug-resistant TB (Fig. 5.2). In light of the growing epidemic of
MDR-TB and lack of new drug development there has been renewed interest in
obsolete compounds for TB (Chang et al. 2013). In 2010, the Damien Foundation
published the results of an observational study, comparing six regimens for
MDR-TB, derived by sequential modiﬁcation. The addition of gatifloxacin and use
of clofozimine throughout the regimen apparently allowed a reduced duration of
treatment, to between 9–12 months, depending on time to smear conversion. All
427 patients received clofazimine in the intensive phase and 206 patients received a
shortened regimen of 9–12 months, using clofazimine throughout treatment [4(+)
KCGEHZP, 5 GCEZ]. Treatment success-rate was highest in the short regimen
Fig. 5.1 Percentage of previously treated TB cases with multidrug-resistant TB. Source WHO,
reprinted with permission
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treatment group with a relapse-free cure of 87.9 % (95 %CI 82.7–91.6), with
relatively good tolerability (Van Deun et al. 2010). This shortened ‘Bangladesh’
regimen is now being subjected to a large multicentre (including sites in Ethiopia,
India, South Africa, Vietnam) randomised controlled trial, known as the STREAM
trial (ISRCTN78372190). The STREAM trial is being conducted by the British
Medical Research Council and will compare the standard MDR regimen (according
to local National TB program guidelines, duration ranging from 18–24 months)
with a modiﬁed form of the Bangladesh regimen. Moxifloxacin, clofazimine, eth-
ambutol and pyrazinamide will be given for nine months, supplemented by kana-
mycin, isoniazid and prothionamide in the four months of the intensive phase. All
drugs are given daily except for kanamycin which is administered thrice weekly
after 12 weeks. The target is to include at least 400 participants. The results of this
major trial are expected in October 2016.




Do not add a single drug to a failing regimen
When starting or modifying therapy, add three previously
unused drugs (one an injectable) to which there is likely to be
susceptibility
Use any of the ﬁrst-line oral agents (Group 1) that are likely to
be effective
In multidrug-resistant tuberculosis (MDR TB), when there is
resistance to additional ﬁrst-line drugs, treat with 4–7 drugs
(dependent on degree of conﬁdence in susceptibility and
strength of derived regimen)
Patients with MDR TB have the highest priority for directly
observed therapy because treatment failure may be associated
with extensively drug-resistant TB
Intermittent therapy should not be used (except for injectables
after 2–3 months)
Do not use drugs to which the M. tuberculosis isolate is
resistant. Low-level resistance to isoniazid may be an exception
There is cross-resistance among rifamycins but not between
streptomycin and other aminoglycosides. Amikacin or
kanamycin are preferred aminoglycosides for MDR as most
MDR strains are resistant to streptomycin
Drug susceptibility testing for pyrazinamide is complex
technically and not performed in most laboratories.
Monoresistance to pyrazinamide suggests M. bovis
Drug susceptibility results for second line agents (except
fluoroquinolones and aminoglycosides) may be unreliable and
should be interpreted within context of treatment history
Levofloxacin, or moxifloxacin are preferred flouroquinolones.
Ciprofloxacin should not be used to treat TB
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5.4 The Role of Fluoroquinolones
The fluoroquinolones levofloxacin, gatifloxacin and moxifloxacin have strong an-
timycobarterial activity with an early bactericidal activity (EBA) similar to that of
isoniazid and are the strongest of the second-line agents. Fluoroquinolones are the
keystone of MDR treatment regimens and should also be considered in cases of
non-MDR drug resistant TB requiring additional agents or if a ﬁrst-line agent in the
standard regimen is not tolerated, particularly in case of hepatotoxicity.
Fluoroquinolones are excreted via the kidneys and thus have a lower potential to
disturb liver function. They inhibit bacterial replication via the DNA gyrase, a
mechanism distinct from those of the ﬁrst-line agents. They have broad-spectrum
antibacterial activity, particularly against gram-negative bacteria, favourable phar-
macokinetic proﬁle, are relatively safe, have good tissue penetration and high
in vitro activity against M. tuberculosis. Fluoroquinolones may therefore work
synergistically to the other TB agents and penetrate well in the tuberculoma.
A recent Cochrane review, evaluating RCTs on ofloxacin, levofloxacin,
moxifloxacin and gatifloxacin, reported that there is insufﬁcient evidence to be clear
whether fluoroquinolones, either added to the ﬁrst-line regimen or as a substitution
for ethambutol or isoniazid, may prevent relapse or death, or increase sputum
culture conversion at 8 weeks (Ziganshina et al. 2013). Three large multicountry
trials have been established to determine if the use of fluoroquinolones can shorten
treatment regimens to four months rather than six: OFLOTUB (NCT00216385),
REMOX TB (NCT00864383) and RIFAQUIN (ISRCTN44153044) studies (Merle
et al. 2014; Gillespie et al. 2014; Jindani et al. 2013). The RIFAQUIN trial reported
in April 2013 and showed inferiority of the four month regimen; Two months of
daily ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two
months of twice weekly moxifloxacin (500 mg) and rifapentine (900 mg) compared
to the standard 6-month WHO regimen (2HRZE/4HR).
The OFLOTUB trial which tested a 4 month regimen of 2 months gatifloxacin
(400 mg/day), isoniazid, rifampicin and pyrazinamide followed by two months
gatifloxacin, isoniazid and rifampicin reported in September 2013 and
(2GHRZ/2GHR) failed to show non-inferiority of the Gatifloxacin regimen at the
pre-speciﬁed 6 % margin (Merle et al. 2014). Although Gatifloxacin has been
banned by the FDA due to toxicity concerns, there was no increased risk of dis-
gylcemia or QTc prolongation with the gatifloxacin regimen. The REMOX trial
which tested two moxifloxacin containing regimens lasting 17 weeks, reported in
2014. The moxifloxacin-containing regimens produced a more rapid initial decline
in bacterial load, as compared with the control group. However, noninferiority for
these regimens was not shown, which indicates that shortening treatment to
4 months was not effective in this setting (Gillespie et al. 2014). Several existing
and newly developed compounds are under evaluation for drug- sensitive and
drug-resistant TB (Fig. 5.2) (Ma et al. 2010; Chang et al. 2013; Gopal et al. 2013).
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5.5 Bedaquiline
Bedaquiline (trade name Sirtuto) is a diarylquinoline drug, formerly known under
its code name TMC207, which was discovered in 2005 by Koen Andries and
colleagues in Belgium. It has a novel mode of action, acting by inhibiting ATP
synthase, and is active against replicating and non-replicating bacilli. The ﬁrst phase
II trial on 47 patients was published in 2009 in the New England Journal of
Medicine and showed that addition of TMC207 to a standard second line regimen
led to a higher proportion of patients with sputum conversion at 8 weeks of
treatment (48 % vs. 9 %), (Diacon et al. 2012). The long-term 2 year follow up
results for this pilot trial were published in 2012 and showed a signiﬁcant reduction
in time to sputum conversion in the TMC207 patients compared to placebo and less
acquisition of resistance to companion drugs in the TMC207 group, however this
did not reach statistical signiﬁcance. With the exception of nausea, which was more
frequently reported in the TMC207 patients, the occurrence of adverse events was
not different between the two groups (Diacon et al. 2014). These results combined
with two other phase II trials have led to accelerated approval of the drug by the
FDA in 2012. This was the ﬁrst new TB drug added to the arsenal of agents in
decades. FDA approval was conditional upon prioritisation of phase three trials, but
these have not yet started. The WHO and CDC have published provisional
guidelines on the use of bedaquiline: http://www.who.int/tb/challenges/mdr/
bedaquiline/en/index.html and http://www.cdc.gov/mmwr/preview/mmwrhtml/
rr6209a1.htm?s_cid=rr6209a1_e (Provisional CDC guidelines for the use and
safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of
multidrug-resistant tuberculosis 2013).
Fig. 5.2 TB drug discovery pipeline
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5.6 Delamanid
Delamanid, (OPC 67683) is a nitro-dihydro-imidazooxazole derivative which acts
by blocking the synthesis of myolic acids, thus interfering with cell-wall integrity of
the mycobacteria. It was ﬁrst proposed to be a potential new candidate for treatment
of TB in 2006 by Japanese scientists working for Otsuka Pharmaceutical.
Subsequently it has shown promising results in phase IIa and b trials. In a seminal
RCT including 481 patients recruited in 17 centers in 9 countries, the proportion of
sputum positive MDR-TB patients that converted to sputum negative after 2 months
of treatment with delamanid (100 mg BID) added to an optimised background
regimen (n = 161) was 45.4 % opposed 29.6 % in those patients receiving a
background regimen and placebo (n = 160) (p = 0.008). The patients receiving
delamanid had signiﬁcantly shorter time to sputum negativity and, additionally, a
mortality beneﬁt was observed for those in the active arms of this trial (Gler et al.
2012). Phase III trials are underway.
The European Medicines Agency (EMA) approved the drug for use in MDR-TB
in November 2013, making Delamanid the second drug to be approved for use in
(MDR-)TB in 50 years. It will be manufactured under the name of Deltyba.
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